Astria Therapeutics (ATXS) Competitors $11.92 +0.31 (+2.67%) Closing price 04:00 PM EasternExtended Trading$11.91 -0.01 (-0.08%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. HROW, BHVN, EWTX, VCEL, GPCR, HRMY, PAHC, SDGR, AUPH, and AVDLShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Harrow (HROW), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Vericel (VCEL), Structure Therapeutics (GPCR), Harmony Biosciences (HRMY), Phibro Animal Health (PAHC), Schrodinger (SDGR), Aurinia Pharmaceuticals (AUPH), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Its Competitors Harrow Biohaven Edgewise Therapeutics Vericel Structure Therapeutics Harmony Biosciences Phibro Animal Health Schrodinger Aurinia Pharmaceuticals Avadel Pharmaceuticals Harrow (NASDAQ:HROW) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends. Does the media prefer HROW or ATXS? In the previous week, Astria Therapeutics had 10 more articles in the media than Harrow. MarketBeat recorded 17 mentions for Astria Therapeutics and 7 mentions for Harrow. Harrow's average media sentiment score of 0.81 beat Astria Therapeutics' score of 0.44 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astria Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, HROW or ATXS? Harrow has higher revenue and earnings than Astria Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M7.31-$17.48M-$0.25-157.76Astria TherapeuticsN/AN/A-$94.26M-$2.01-5.93 Which has more volatility and risk, HROW or ATXS? Harrow has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Is HROW or ATXS more profitable? Astria Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-4.49% -2.18% -0.35% Astria Therapeutics N/A -56.39%-36.08% Do analysts recommend HROW or ATXS? Harrow currently has a consensus target price of $68.50, suggesting a potential upside of 73.68%. Astria Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 109.73%. Given Astria Therapeutics' higher probable upside, analysts plainly believe Astria Therapeutics is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Astria Therapeutics 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do institutionals & insiders have more ownership in HROW or ATXS? 72.8% of Harrow shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 13.7% of Harrow shares are held by company insiders. Comparatively, 4.5% of Astria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryHarrow beats Astria Therapeutics on 9 of the 16 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$672.77M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-5.9322.9285.4427.36Price / SalesN/A270.00515.26195.91Price / CashN/A46.9537.5761.53Price / Book3.0010.5512.426.82Net Income-$94.26M-$52.58M$3.32B$276.89M7 Day Performance41.90%1.09%1.01%0.27%1 Month Performance61.74%16.09%10.75%8.31%1 Year Performance3.74%18.41%76.20%35.60% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics2.1874 of 5 stars$11.92+2.7%$25.00+109.7%+4.9%$672.77MN/A-5.9330Trending NewsAnalyst DowngradeHigh Trading VolumeHROWHarrow2.7597 of 5 stars$42.16-7.2%$68.50+62.5%-22.7%$1.68B$199.61M-168.64180High Trading VolumeBHVNBiohaven2.9727 of 5 stars$15.93+0.8%$48.85+206.6%-68.6%$1.67BN/A-2.08239EWTXEdgewise Therapeutics2.805 of 5 stars$15.35-1.9%$38.83+153.0%-53.8%$1.65BN/A-9.9060VCELVericel3.3517 of 5 stars$33.74+4.0%$60.40+79.0%-17.7%$1.64B$237.22M281.19300Analyst ForecastAnalyst RevisionGPCRStructure Therapeutics3.2059 of 5 stars$28.68+5.1%$68.67+139.4%-17.7%$1.57BN/A-27.31136Positive NewsHRMYHarmony Biosciences4.7069 of 5 stars$26.59-2.5%$45.50+71.1%-24.4%$1.57B$714.73M8.58200Analyst ForecastPAHCPhibro Animal Health4.2956 of 5 stars$37.79-1.4%$28.40-24.8%+55.0%$1.55B$1.30B32.032,475Analyst ForecastSDGRSchrodinger2.6462 of 5 stars$21.29+3.4%$26.57+24.8%+9.0%$1.52B$207.54M-8.58790Analyst ForecastGap UpAUPHAurinia Pharmaceuticals3.1875 of 5 stars$11.32-0.3%$13.00+14.8%+57.7%$1.49B$235.13M26.33300Positive NewsAVDLAvadel Pharmaceuticals2.7166 of 5 stars$14.53-3.2%$20.86+43.5%+9.1%$1.46B$169.12M-484.3370 Related Companies and Tools Related Companies Harrow Competitors Biohaven Competitors Edgewise Therapeutics Competitors Vericel Competitors Structure Therapeutics Competitors Harmony Biosciences Competitors Phibro Animal Health Competitors Schrodinger Competitors Aurinia Pharmaceuticals Competitors Avadel Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
